The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Abstract
BACKGROUND: Some reports indicate that fibrates can induce renal dysfunction. However, the clinical characteristics of these episodes, and the respective nephrotoxicity of the four main fibrates used-namely, fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil-remain ill defined. METHODS: To better characterize this side-effect, we first reviewed the charts of 27 patients from our institution who developed an impairment of renal function during fibrate therapy. We next analysed the articles (n=24) that contained data on renal function in patients taking fibrates (n=2676). RESULTS: Among our 27 patients, 25 were on fenofibrate therapy, one was taking bezafibrate, and one ciprofibrate. Nineteen were recipients of solid-organ transplants (kidney recipients, n=15; heart or heart-lung recipients, n=4), and eight were non-transplanted patients with some impairment of renal function. Baseline plasma creatinine ranged from 0.9 to 2.9 mg/dl. It increased by a mean of 40% after the start of fibrate therapy. There was a concomitant increase of blood urea values (mean 36%) in most of the patients. Renal function returned to baseline in 18/24 patients after fibrate discontinuation. However, six patients, all transplant recipients, experienced a permanent increase in plasma creatinine. The incidence of fibrate-induced renal dysfunction among our series of kidney transplant recipients was 60%, as it occurred in 15 of the 25 patients who had ever taken fibrates. An increase of mean creatinine values during therapy was described in all papers on fenofibrate (n=7) and bezafibrate (n=8) (range 8-18% and 8-40% respectively), and in three of four papers dealing with ciprofibrate (range 6-16%). No significant renal impairment was described in any of the eight articles reporting data on gemfibrozil therapy. CONCLUSION: Therapy with fenofibrate, bezafibrate, and ciprofibrate may induce renal dysfunction. Gemfibrozil appears to be devoid of this side-effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Drug-induced elevations in serum creatinine have been reported in those with mild to moderate renal failure (46) and renal transplant recipients (47,48)”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,230
Plasma triglyceride and coronary heart disease
Austin, M. A. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.2 · Cited by 697 · cited 1×
“To better characterize this side-effect, we important risk factors for the development of atherofirst reviewed the charts of 27 patients from our sclerosis [1–3].”
BackgroundBiochemical Mechanisms Of Induction Of Hepatic Peroxisome Proliferation
Lock, E. A., Mitchell, A. M., & Elcombe, C. R. (1989) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.29.040189.001045 · Cited by 424
Hyperlipidemia in patients with chronic renal disease
Kasiske, B. L. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820472 · Cited by 283
Ellen, R., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 175
Serum homocysteine increases after therapy with fenofibrate or bezafibrate
Dierkes, J., Westphal, S., & Luley, C. H. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02153-4 · Cited by 144
Research works printed but not linked: 2
- Orö L, Carlson LA, Olsson A, Poole PH. Long‐term efficacy and safety of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res1992; 51: 750–762
- de Gennes JL, Truffert J, Dairou F. Evaluation de l'activité hypolipidémiante et de la tolérance du ciprofibrate. Sem Hop1985; 61: 2807–2812
Cited by
Sorted by citations
Items 101–163 of 163
Lever, M., McEntyre, C. J., George, P. M., Slow, S., Chambers, S. T., & Foucher, C. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.04.001 · Cited by 10
Salgueiro, G., Beltrán, L. M., Torres, R. J., & Puig, J. G. (2014) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2013.854382 · Cited by 10
Lipid Management in Chronic Kidney Disease, Hemodialysis, and Transplantation
Montague, T., & Murphy, B. T. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.004 · Cited by 10
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study
Iwasaki, M., Suzuki, H., Umezawa, Y., Koshida, T., Saito, M., Fukuda, H., Takahara, H., Matsuzaki, K., & Suzuki, Y. (2023) · Medicine · doi:10.1097/md.0000000000032818 · Cited by 10
Cessation of Bezafibrate in patients with chronic kidney disease improves renal function
Zingerman, B. V., Ziv, D., Krengel, N. F., Korzets, A., & Matok, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-76861-1 · Cited by 7
Fenofibrate can increase serum creatinine levels in renal insufficiency.
Paul, S. B., & Mohan, V. (2006) · PubMed · Cited by 7
Golla, K., Mannell, H., Benesic, A., Dreischulte, T., Grill, E., & Strobach, D. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13597 · Cited by 6
Management of Hyperlipidemia in the Stable Solid Organ Transplant Recipient
Abtahi, P., & Zand, M. S. (2001) · Graft · doi:10.1177/152216280100400405 · Cited by 6
The use of fenofibrate in diabetic retinopathy: Narrative review
Dissanayake, H. A., Kiire, C. A., Preiss, D., & Tan, G. D. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109135 · Cited by 5
Fenofibrate and renal disease: clinical effects in diabetes
Ting, R.-D., & KEECH, A. C. (2013) · Clinical Lipidology · doi:10.2217/clp.13.69 · Cited by 5
Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia
Τζιόμαλος, Κ., Ganotakis, E. S., Gazi, I. F., Nair, D. R., & Mikhailidis, D. P. (2009) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192400903010057 · Cited by 5
Role of Dyslipidemia in Patients With Chronic Kidney Disease
Marino, A., & Tannock, L. R. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.07.2676 · Cited by 5
Cho, J. H., Choi, Y. H., Hyeon, C. W., Kim, K. J., Hyun, S., Kwon, J. E., Kim, E. Y., Lee, W. S., Lee, K. J., Kim, S., et al. (2013) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2013.2.1.19 · Cited by 4
Liu, J., Kalantarinia, K., & Rosner, M. H. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00193.x · Cited by 4
Management of Dyslipidemia in Patients After Solid Organ Transplantation
Tannock, L. R., & Reynolds, L. R. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.04.1759 · Cited by 4
Care of the Liver Transplant Patient
Kallwitz, E. R., & Cotler, S. J. (2008) · Disease-a-Month · doi:10.1016/j.disamonth.2008.03.003 · Cited by 4
Yen, T., Chang, C.-T., Wu, M.-S., & Huang, C. (2003) · Renal Failure · doi:10.1081/jdi-120017477 · Cited by 4
Young, I. S., & Woodside, J. V. (2001) · Nutrition · doi:10.1016/s0899-9007(01)00682-7 · Cited by 4
Shields, C. A., Poudel, B., McPherson, K. C., Brown, A. K., Ekperikpe, U. S., Browning, E., Sutton, L., Cornelius, D. C., & Williams, J. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.566403 · Cited by 3
Hypertriglyceridaemia: Aetiology, Complications and Management
Blom, D. J. (2010) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2010.10872218 · Cited by 3
Hypertriglyceridaemia: Aetiology, complications and management
Blom, D. J. (2010) · South African Family Practice · doi:10.1080/20786204.2010.10873948 · Cited by 3
Wu, Z., Zhao, Y., Hao, S., An, M., Song, C., & Li, J. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01371 · Cited by 4
Regemorter, E. V., Ponlot, E., Boland, L., Gillion, V., & Devresse, A. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106592 · Cited by 2
Kang, Y.-R., Kwak, C. H., & Hwang, J. (2007) · Korean Circulation Journal · doi:10.4070/kcj.2007.37.12.599 · Cited by 2
Park, G. T., Jung, M., Kim, Y., Cho, I., Won, H., Shin, S. Y., Lee, W. S., Lee, K. J., Kim, S., Kim, T. H., et al. (2017) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2017.6.2.89 · Cited by 2
Ovcharenko, E., Hansen, M. K., Goltsman, I., Abu‐Saleh, N., Abassi, Z. A., Walsh, K. R., Miele, G., Feuerstein, G., & Winaver, J. M. (2010) · Nephron Physiology · doi:10.1159/000314541 · Cited by 3
Exploration de la fonction glomérulaire rénale (I). Méthodes de référence et créatinine sérique
Delanaye, P., Maillard, N., Thibaudin, L., & Mariat, C. (2011) · Encyclopédie médico-chirurgicale. Néphrologie · doi:10.1016/s1762-0945(11)44016-x · Cited by 2
An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual
Bruno, C. B., Schapiro, J. M., & Saberi, P. (2011) · Journal of the International Association of Physicians in AIDS Care · doi:10.1177/1545109711404945 · Cited by 2
Élévation de la créatinine sérique imputée aux fibrates : à propos de deux cas
Décaudin, B., Béraud, G., Lannoy, D., Semjen, E., Wierre, L., Horrent, S., Resibois, J., Azar, R., & Odou, P. (2005) · Therapies · doi:10.2515/therapie:2005089 · Cited by 2
Hyeon, C. W., Choi, Y. H., Hyun, S., Kwon, J. E., Kim, E. Y., Shin, S. Y., Lee, W. S., Lee, K. J., Kim, S., Kim, T. H., et al. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.6.702 · Cited by 1
The Role of Dyslipidemias in the Progression of Chronic Kidney Disease
Farbakhsh, K., & Kasiske, B. L. (2008) · Elsevier eBooks · doi:10.1016/b978-012088488-9.50094-2 · Cited by 1
Special Patient Populations: Chronic Renal Disease
Jardine, A. G., Mark, P. B., Holdaas, H., & Fellström, B. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50045-7 · Cited by 1
Ponticelli, C. (2007) · CRC Press eBooks · doi:10.3109/9780203089903-7 · Cited by 1
NIKKANEN, H. E., & Shannon, M. W. (2007) · Elsevier eBooks · doi:10.1016/b978-0-7216-0693-4.50021-9 · Cited by 1
Insuficiencia renal asociada al uso de fibratos (n = 46)
Casas, C. R. C., Díaz, B. M., Tabarés, L. G., Gomez‐Larrambe, N., González, L. C., Merino, M. L. G., & Varela, J. C. (2016) · Nefrología · doi:10.1016/j.nefro.2016.09.013 · Cited by 1
Effect of Curcmin on Chronic Kidney Disease of Expermintal Rats
Mahmod, S. A. A., & Fahmy, T. S. (2021) · Bulletin of the National Nutrition Institute · doi:10.21608/enj.2021.209230 · Cited by 1
How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly
Turgut, F. H., Üstün, İ., & Gökçe, C. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_4
Effets secondaires des médicaments: Des conséquences indésirables aux effets recherchés
Cogan, E. (2006) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles)
Role of Primary Care Provider in the Referral and Care of Thoracic Organ Transplant Patients
Bag, R., Bhimaraj, A., & Garikipati, S. (2014) · doi:10.1002/9781118873434.ch35
Immunosuppressive Agents for the Prevention of Transplantation Rejection
Pitts, W. J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc206
HYPERCHOLESTEROLEMIA AND CHRONIC REJECTION OF RENAL ALLOGRAFTS
Wissing, K. M., & Abramowicz, D. (2001) · Transplantation · doi:10.1097/00007890-200108270-00038
Self-citationof Fenofibrate Therapy- Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Mychaleckyj, J. C., Craven, T. E., Buse, J. B., Crouse, J. R., Elam, M. B., Kirchner, K. A., Lorber, D., Sivitz, W. I., Sperl‐Hillen, J. M., Bonds, D. E., et al. (2012)
Kidney Disease in Obesity and Metabolic Syndrome
Rosas, S. E., William, J. H., & Kramer, H. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_49-1
Fibrates: Risk Benefits and Role in Treating Dyslipidemias
Jun, M., & Perkovic, V. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_25
Lipid disorders of patients with chronic kidney disease
Jardine, A. G., & Patel, R. K. (2015) · doi:10.1093/med/9780199592548.003.0102
Renal failure related to fibrates administration ( n = 46)
Casas, C. R. C., Díaz, B. M., Tabarés, L. G., Gomez‐Larrambe, N., González, L. C., Merino, M. L. G., & Varela, J. C. (2017) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2017.04.006
Drugs for Treatment of Dyslipidemia Available in the USA
Streja, E., & Streja, D. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_13
Fibrates in Chronic Kidney Disease Patients: A Controversial Issue
Baki, A. H., & Zarif, J. K. (2020) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2020.118574
Innovative Lipid Biomarkers and Long-Term Outcomes
Anderson, J. L. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192996734
(2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00125-2
Kidney Disease in Obesity and Metabolic Syndrome
William, J. H., Kramer, H., & Rosas, S. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_49-2
Ponticelli, C. (2007) · CRC Press eBooks · doi:10.3109/9780203089903-11
Kidney Disease in Obesity and Metabolic Syndrome
William, J. H., Kramer, H., & Rosas, S. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_49
Guan, Y., & Breyer, M. D. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00129-2.x
Fibrate-induced renal dysfunction not seen with gemfibrozil
&NA; (2001) · Reactions Weekly · doi:10.2165/00128415-200108350-00007
Use of ciprofibrate in dogs with hypertriglyceridemia
González, F., de Marco, M., Valenci, D., & Bustos, D. (2023) · Journal of Dairy Veterinary & Animal Research · doi:10.15406/jdvar.2023.12.00318
Mark, P. B., Jardine, A. G., & Patel, R. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00038-8
Meyer, J. M., & Stahl, S. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009225069.005
Jardine, A. G., Mark, P. B., Patel, R. K., Holdaas, H., & Fellström, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00041-4
Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · medRxiv · doi:10.64898/2026.01.01.26343323
Cholesterol: an ancient ally or modern menace?
Luna-Reyes, I., Villa-Jaimes, S., Calixto-Tlacomulco, S., Pérez-Hernández, E. G., Montalvan‐Sorrosa, D., Reyes‐Grajeda, J. P., & Mas‐Oliva, J. (2026) · Royal Society Open Science · doi:10.1098/rsos.250853
Song, J., Dou, C.-Y., Chen, X., Hu, J. K., Xu, F., Li, L.-C., Li, J., Jiang, Q., & Zheng, W. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05302-z
Metadata
- Authors
- Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D.
- Affiliations
- Erasmus Hospital (BE)
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12-01
- Volume
- 15
- Issue
- 12
- Pages
- 1993-1999
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2099822840
- Cited by
- 163
- References
- 39
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 8
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- fibrates, nephrotoxicity, renal dysfunction, gemfibrozil, fenofibrate, bezafibrate, ciprofibrate, blood urea, serum creatinine, kidney transplant recipients, drug-induced nephrotoxicity
- MeSH terms
- Hypolipidemic Agents, Bezafibrate, Clofibric Acid, Creatinine, Humans, Kidney Diseases, Postoperative Period, Fenofibrate, Retrospective Studies, Urea, Gemfibrozil, Kidney Transplantation, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
